33 results
Thumbnail

D3.140 - Transcriptomic profiling reveals distinct gene signatures and immune pathways in inhaled corticosteroid (ICS)-sensitive and resistant House Dust Mite (HDM)-induced asthma mouse models

Thumbnail

D3.141 - Serum levels of IL-10 and IFN-GAMMA in adolescents diagnosed with asthma in clinical remission without treatment

Thumbnail

D3.142 - Adherence to Inhaled Corticosteroid Therapy in Patients with Severe Asthma at a Danish Tertiary Care Centre

Thumbnail

D3.143 - Immunomodulatory role of vitamin D in severe asthma: a potential biomarker of treatment response

Thumbnail

D3.144 - Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?

Thumbnail

D3.145 - Comparative particle size and distribution from fixed dose triple dry powder inhalers

Thumbnail

D3.146 - Attitudes and Knowledge Levels Regarding Physical Activity in Children with Asthma and Their Parents: A Comparison with Healthy Controls

Thumbnail

D3.147 - A Survey of Approaches to Inhaled Therapy Management in Patients with Severe Asthma Treated with Biologics: Practices Among REIMAGINE Study Sites

Thumbnail

D3.148 - ANCA-Negative Systemic Vasculitis Developing Despite Anti-IL-5R Therapy and High Dose of Glucocorticosteroids: A Diagnostic and Therapeutic Challenge

Thumbnail

D3.149 - Nationwide Trends in Asthma-Related Mortality in Türkiye: Impact of the Sex-Specific Differences (2018–2024)

Thumbnail

D3.150 - Clinical characterization of patients affected by asthma and psoriasis or psoriasic arthritis: an observational retrospective study

Thumbnail

D3.151 - Anti-IL5 biologics in eosinophilic granulomatosis with polyangiitis patients followed in a severe asthma multidisciplinary unit: functional and clinical outcomes

Thumbnail

D3.152 - The quality of life in severe asthma patients treated with biologics is better than those with triple inhaler therapy

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria